Lucid Diagnostics (NASDAQ:LUCD) Price Target Cut to $2.00 by Analysts at Cantor Fitzgerald

Lucid Diagnostics (NASDAQ:LUCD) had its price objective cut by analysts at Cantor Fitzgerald from $3.00 to $2.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price points to a potential upside of 99.00% from the company’s previous close.

A number of other equities analysts also recently issued reports on the company. Canaccord Genuity Group upgraded Lucid Diagnostics to a “strong-buy” rating in a research note on Tuesday, August 13th. Ascendiant Capital Markets decreased their price objective on shares of Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating on the stock in a research report on Tuesday, September 10th. Canaccord Genuity Group reissued a “buy” rating and issued a $3.00 price target on shares of Lucid Diagnostics in a report on Thursday. Finally, Needham & Company LLC reissued a “buy” rating and set a $2.50 price objective on shares of Lucid Diagnostics in a report on Thursday. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $3.69.

Lucid Diagnostics Stock Down 0.5 %

Lucid Diagnostics stock traded down $0.01 during trading hours on Friday, hitting $1.01. The stock had a trading volume of 47,993 shares, compared to its average volume of 193,492. The stock’s 50-day moving average price is $0.87 and its 200-day moving average price is $0.85. The stock has a market capitalization of $54.26 million, a P/E ratio of -0.88 and a beta of 1.41. Lucid Diagnostics has a 12-month low of $0.63 and a 12-month high of $1.58.

Lucid Diagnostics (NASDAQ:LUCD) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter. The firm had revenue of $0.98 million during the quarter. On average, research analysts expect that Lucid Diagnostics will post -0.82 EPS for the current fiscal year.

Institutional Trading of Lucid Diagnostics

A hedge fund recently raised its stake in Lucid Diagnostics stock. Virtu Financial LLC increased its holdings in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) by 66.4% in the first quarter, according to its most recent filing with the SEC. The fund owned 34,671 shares of the company’s stock after acquiring an additional 13,835 shares during the period. Virtu Financial LLC owned about 0.07% of Lucid Diagnostics worth $28,000 at the end of the most recent quarter. Institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.